A. Merenlender Wagner - Innovative Medicines R&D, Teva Pharmaceuticals

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 5 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Pharmacokinetic modeling and simulation of D2 receptor occupancy following doses of TV-46000, a long-acting subcutaneous antipsychotic agent

I. Perlstein,A. Merenlender Wagner, A. Elgart,R. Singh, A. Zandvliet, F. Hellmann, Y. Lin, E. Van Maanen, N. Plock, F. Fauchet

Neuroscience Applied (2023): 102506

引用0浏览0引用

Evaluation of the pharmacokinetics of TV-44749, newly developed once-monthly extended-release formulation of olanzapine in healthy volunteers and patients with schizophrenia

I. Cherniakov,A. Merenlender Wagner, A. Elgart, R. Eshet, S. Swanson, R. Tiver, D. Bibi, I. Perlstein, R. Bilgraer, A. Kalmanczhelyi, N. Sharon, K. Ferderber,

Neuroscience Applied (2023): 102503

引用0浏览0引用

Population pharmacokinetic modeling of total active moiety exposure following doses of TV-46000, a long-acting subcutaneous antipsychotic injection

I. Perlstein,A. Merenlender Wagner, A. Elgart,R. Singh, A. Zandvliet, F. Hellmann, Y. Lin, E. Van Maanen, N. Plock, F. Fauchet

Neuroscience Applied (2023): 102509

引用0浏览0引用

Population pharmacokinetic modeling and simulation to guide dose selection for TV-46000, a new long-acting formulation of risperidone for subcutaneous injection

I. Perlstein,A. Merenlender Wagner, M. Lamson, O. Spiegelstein, P. Loupe, R. Gomeni, A. Elgart

European Neuropsychopharmacology (2021): S338-S338

引用0浏览0引用

Phase 1 open-label study assessing the pharmacokinetics and safety of TV-46000, a novel long-acting subcutaneous injectable formulation of risperidone

A. Merenlender Wagner, A. Elgart,I. Perlstein, M. Lamson, R. Tiver, A. Kalmanczhelyi, O. Spiegelstein, A. Mackellar, E. Harary

European Neuropsychopharmacology (2021): S339-S340

引用0浏览0引用

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn